Industries > Pharma > The Prostate Cancer Therapeutics Market 2013-2023

The Prostate Cancer Therapeutics Market 2013-2023

PUBLISHED: 17 September 2013
PAGES: 161
PRODUCT CODE:

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: N/A Categories: , ,

Prostate cancer therapeutics – assess products, developments, and revenue prospects

How are the leading segments in the prostate cancer therapeutics market performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study lets you assess leading drugs and devices in the prostate cancer therapeutics market, showing their prospects to 2023. There you see financial results, interviews, trends, opportunities, and revenue predictions. You will also find information on pipeline drugs in the market.  

Forecasts and other data to help you stay ahead

In our new study you find revenue forecasts of eight leading drugs and five device segments along with an analysis of the overall industry- with historical data, revenue forecasts, growth rates, and market shares. Discover a qualitative analysis too. You also gain 69 figures, 67 tables and an interview with an authority in the industry.

Our work lets you assess the most lucrative parts of the world market for prostate cancer therapeutic products. See now how you can benefit your research, analyses, and decisions there, also saving time.

The following sections highlight what you find in our new investigation.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting for the main submarkets at world level:
• Prostate cancer drugs
• Prostate cancer devices

See forecasts for prostate cancer drugs

How will drugs perform to 2023 at world level? Our study predicts individual revenues of these products:
• Zytiga
• Lupron
• Zoladex
• Casodex
• Taxotere
• Provenge
• Jevtana
• Xtandi

How will the prostate cancer devices market perform to 2023 at world level? Our study predicts individual revenues of the main devices submarkets, including these:
• The brachytherapy market
• The radical prostatectomy market
• The external beam radiation market
• The cryotherapy market
• The HIFU market

There you discover how high sales can go, to 2023.

Prospects for leading countries shown to 2023

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for prostate cancer therapies.

You discover revenue forecasts to 2023 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy, and Spain (EU5 nations)
• India
• China
• Brazil
• Russia.

This decade, revenues from India and China will be among the fastest growing worldwide.

Issues affecting the manufacturing and selling of prostate cancer therapies

In addition, our report discusses issues and events affecting that industry and market from 2013, including these:
• Drugs targeting mCRPC – driving market growth
• Strong pipeline of drugs in development
• Robotic prostatectomy – showing strong growth potential
• Prostate cancer market driven by an aging population
• Expansion internationally – targeting emerging national markets
• Stem cells – offer opportunities for growth
• High rivalry among competitors

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

Our work shows you what technologies and organisations hold greatest potential. See profiles of five leading companies, including these:
• Johnson and Johnson
• AstraZeneca
• Varian Medical Systems

In general, a company profile gives you the following information
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of its developments – mergers and acquisitions (M&A), new products, and collaborations.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Ways The Prostate Cancer Therapeutics Market 2013-2023 helps you

In summary, then, our new research and analysis give you the following knowledge:
• Revenues to 2023 for the world prostate cancer therapeutics market and its submarkets – discover that industry's prospects, finding promising places for investments and revenues
• Potential revenues of leading products to 2023
• Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia
• Competition and opportunities – see what affects the prostate cancer therapeutics market, learning what shapes its future, esp. prospects for sustaining and developing business
• Assessment of companies – discussions of activities and outlooks
• Review of R&D pipelines by submarket – progress and trends

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Ordering now lets you discover prospects for prostate cancer therapies

Visiongain's study is for everybody needing commercial analyses of prostate cancer therapies. You find data, trends and predictions there. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for The Prostate Cancer Therapeutics Market 2013-2023


Download sample pages

Complete the form below to download your free sample pages for The Prostate Cancer Therapeutics Market 2013-2023


Latest Pharma news

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

READ

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

READ

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

READ

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

READ

Categories